Pacira Pharma's (PCRX) Exparel Could Be $1 Billion Product
Tweet Send to a FriendGet Alerts PCRX Hot Sheet
Price: $29.44 +0.93%
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
5 Buy, 0 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade PCRX Now!
Pacira Pharmaceuticals (NASDAQ: PCRX) presented at Jefferies' London conference. During the presentation, it highlighted strong momentum in November Exparel sales.
"The stock pulled back as Q3 sales of $4.6M were a little light, but now seems an ideal re-entry point," said analyst Corey Davis.
During the presentation, Pacira made the point that a 10 percent penetration of the 40 million relevant surgical procedures would make Exparel a $1 billion product.
Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a price target of $22.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $15.27 yesterday, with a 52 week range of $6.99-$19.31.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
"The stock pulled back as Q3 sales of $4.6M were a little light, but now seems an ideal re-entry point," said analyst Corey Davis.
During the presentation, Pacira made the point that a 10 percent penetration of the 40 million relevant surgical procedures would make Exparel a $1 billion product.
Jefferies has a Buy rating on Pacira Pharmaceuticals (NASDAQ: PCRX) with a price target of $22.00.
For an analyst ratings summary and ratings history on Pacira Pharmaceuticals click here. For more ratings news on Pacira Pharmaceuticals click here.
Shares of Pacira Pharmaceuticals closed at $15.27 yesterday, with a 52 week range of $6.99-$19.31.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Topeka Capital Starts Laredo Petroleum (LPI) at Buy, Assets 'Undervalued'
- UBS Survey Shows Signs of Strength for Gilead's (GILD) TAF
Create E-mail Alert Related Categories
Analyst Comments, Analyst EPS ViewRelated Entities
Jefferies & Co
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
